These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 30634339)

  • 1. Re: Role of the 4Kscore Test as a Predictor of Reclassification in Prostate Cancer Active Surveillance.
    Taneja SS
    J Urol; 2019 Feb; 201(2):228. PubMed ID: 30634339
    [No Abstract]   [Full Text] [Related]  

  • 2. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.
    Welty CJ; Cowan JE; Nguyen H; Shinohara K; Perez N; Greene KL; Chan JM; Meng MV; Simko JP; Cooperberg MR; Carroll PR
    J Urol; 2015 Mar; 193(3):807-11. PubMed ID: 25261803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 4Kscore blood test accurately identifies men with aggressive prostate cancer prior to prostate biopsy with or without DRE information.
    Zappala SM; Dong Y; Linder V; Reeve M; Sjoberg DD; Mathur V; Roberts R; Okrongly D; Newmark J; Sant G; Steiner M
    Int J Clin Pract; 2017 Jun; 71(6):. PubMed ID: 28497893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of predictors of unfavorable pathological features in men eligible for active surveillance using radical prostatectomy specimens: a multi-institutional study.
    Mizuno K; Inoue T; Kinoshita H; Yano T; Kawanishi H; Kanda H; Terada N; Kobayashi T; Kamba T; Mikami Y; Shiraishi T; Uemura Y; Imai Y; Honjo G; Shirase T; Okumura K; Kawakita M; Ogura K; Sugimura Y; Matsuda T; Ogawa O
    Jpn J Clin Oncol; 2016 Dec; 46(12):1156-1161. PubMed ID: 27744325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy.
    Kovac E; Lieser G; Elshafei A; Jones JS; Klein EA; Stephenson AJ
    J Urol; 2017 Jan; 197(1):84-89. PubMed ID: 27449260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer patients eligible for active surveillance.
    Ploussard G; de la Taille A; Terry S; Allory Y; Ouzaïd I; Vacherot F; Abbou CC; Salomon L
    Urol Oncol; 2013 Oct; 31(7):1060-6. PubMed ID: 22300755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
    Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
    BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols.
    Kates M; Tosoian JJ; Trock BJ; Feng Z; Carter HB; Partin AW
    BJU Int; 2015 Feb; 115(2):216-22. PubMed ID: 24904995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance.
    San Francisco IF; Rojas PA; DeWolf WC; Morgentaler A
    BJU Int; 2014 Aug; 114(2):229-35. PubMed ID: 24898919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Villers A; Olivier J
    Eur Urol; 2018 Sep; 74(3):396. PubMed ID: 29650234
    [No Abstract]   [Full Text] [Related]  

  • 11. Transurethral resection of the prostate for patients with Gleason score 6 prostate cancer and symptomatic prostatic enlargement: a risk-adaptive strategy for the era of active surveillance.
    Koo KC; Park SU; Rha KH; Hong SJ; Yang SC; Hong CH; Chung BH
    Jpn J Clin Oncol; 2015 Aug; 45(8):785-90. PubMed ID: 25979243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Preliminary Study of the Ability of the 4Kscore test, the Prostate Cancer Prevention Trial-Risk Calculator and the European Research Screening Prostate-Risk Calculator for Predicting High-Grade Prostate Cancer.
    Borque-Fernando Á; Esteban-Escaño LM; Rubio-Briones J; Lou-Mercadé AC; García-Ruiz R; Tejero-Sánchez A; Muñoz-Rivero MV; Cabañuz-Plo T; Alfaro-Torres J; Marquina-Ibáñez IM; Hakim-Alonso S; Mejía-Urbáez E; Gil-Fabra J; Gil-Martínez P; Ávarez-Alegret R; Sanz G; Gil-Sanz MJ
    Actas Urol Esp; 2016 Apr; 40(3):155-63. PubMed ID: 26598800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Risk Group and Death from Prostate Cancer: Implications for Active Surveillance in Men with Favorable Intermediate-Risk Prostate Cancer.
    Taneja SS
    J Urol; 2016 Aug; 196(2):412-3. PubMed ID: 27479379
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Active Surveillance in Younger Men with Prostate Cancer.
    Özen H; Türkeri LN
    Eur Urol; 2018 May; 73(5):807. PubMed ID: 29273409
    [No Abstract]   [Full Text] [Related]  

  • 15. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer.
    Basourakos SP; Davis JW; Chapin BF; Ward JF; Pettaway CA; Pisters LL; Navai N; Achim MF; Wang X; Chen HC; Choi S; Kuban D; Troncoso P; Hanash S; Thompson TC; Kim J
    BJU Int; 2018 Jan; 121(1):69-76. PubMed ID: 28710901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Active Surveillance of Prostate Cancer in a Community Practice: How to Measure, Manage, and Improve?
    Penson DF
    J Urol; 2017 Mar; 197(3 Pt 1):703. PubMed ID: 28208525
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Quantified Clinical Risk Change as an End Point during Prostate Cancer Active Surveillance.
    Taneja SS
    J Urol; 2017 Mar; 197(3 Pt 1):699-700. PubMed ID: 28208519
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer.
    Penson DF
    J Urol; 2017 Jan; 197(1):153-154. PubMed ID: 27979510
    [No Abstract]   [Full Text] [Related]  

  • 19. Multiparametric magnetic resonance imaging characterization of prostate lesions in the active surveillance population: incremental value of magnetic resonance imaging for prediction of disease reclassification.
    Bonekamp D; Bonekamp S; Mullins JK; Epstein JI; Carter HB; Macura KJ
    J Comput Assist Tomogr; 2013; 37(6):948-56. PubMed ID: 24270118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Active Surveillance in Younger Men with Prostate Cancer.
    Taneja SS
    J Urol; 2017 Oct; 198(4):741-745. PubMed ID: 28905784
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.